Biointron’s Q2 2025 Antibody Industry Report aims to explore the events and trends of the biopharmaceutical industry in April, May, and June. This quarter, 5 novel monoclonal antibody drugs have been approved by at least one regulatory agency around the world: three from US, one from EU, and one from China.
Linvoseltamab (Lynozyfic)
Nipocalimab (Imaavy)
Telisotuzumab Vedotin (Emrelis)
Trastuzumab Rezetecan
Clesrovimab (Enflonsia)
Instead of M&As, Q2 2025 saw pharmaceutical companies making large licensing transactions, such as one collaboration with a potential $11.1 billion value. Investment into antibody drug startups have focuses across novel antibody modalities and autoimmune disease targets.
Gain exclusive insights into current trends such as:
5 novel antibody drugs approved for the first time in Q2
Top 10 antibody drug deals, including licensing agreements, strategic partnerships, and funding rounds of up to US$11.1B
Current research into the disease area of non-small cell lung cancer (NSCLC)
Multi-payload antibody-drug conjugates as a recent innovation
A list of antibody drugs with soon approaching approval action dates to keep an eye out for in Q3 2025
Biointron’s Q2 2026 Antibody Industry Trends report aims to explore the events a……
Autoimmune diseases are a group of disorders in which the immune system targets ……
Antibodies are important raw materials for many in vitro diagnostic (IVD) applic……
For decades, many disease-driving proteins were described as undruggable because……
You can also contact us on the Scientist and Science Exchange marketplaces.